Literature DB >> 14510993

Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse.

M J Cork1, J Britton, L Butler, S Young, R Murphy, S G Keohane.   

Abstract

BACKGROUND: The failure of patients to take medicines in a way that leads to clinical benefit is a major challenge. A consensus has emerged that, on average, compliance sufficient to obtain therapeutic objectives occurs about half the time, with noncompliance contributing to therapeutic failure in the other half. These figures refer to simple oral regimens. There has been little work assessing compliance/concordance with complex treatment regimens for atopic eczema. Asthma schools led by specialist nurses have been shown to improve knowledge, use of therapies and clinical outcome.
OBJECTIVES: To determine the effect of education and demonstration of topical therapies by specialist dermatology nurses on therapy utilization and severity of atopic eczema.
METHODS: Fifty-one children with atopic eczema attending a paediatric dermatology clinic were followed for up to 1 year. At each visit the parent's knowledge about atopic eczema and its treatment and therapy utilization was recorded. The severity of the eczema was recorded using the six area, six sign atopic dermatitis severity score (SASSAD) and parental assessment of itch, sleep disturbance and irritability. At the first visit a specialist dermatology nurse explained and demonstrated how to use all of the topical treatments. This education was repeated at subsequent visits depending on the knowledge of the parent.
RESULTS: At baseline less than 5% of parents had received/recalled receiving any explanation of the causes of eczema or demonstration of how to apply topical treatments. The eczema was poorly controlled in all children (mean SASSAD 42.9). Of the children, 24% were not being treated with any emollient cream/ointment; the mean use was 54 g weekly. Of the children, 25% were being inappropriately treated with potent or very potent topical steroids. Following repeated education and demonstration of topical therapies by a specialist dermatology nurse, there was an 89% reduction in the severity of the eczema. The main change in therapy utilization was an 800% increase in the use of emollients (to 426 g weekly of emollient cream/ointment) and no overall increase in the use of topical steroids, accounting for potency and quantity used.
CONCLUSIONS: This study reinforces the importance of specialist dermatology nurses in the management of atopic eczema. It also confirms the opinion of patients, patient support groups, dermatologists and best practice guidelines that the most important intervention in the management of atopic eczema is to spend time to listen and explain its causes and demonstrate how to apply topical therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510993     DOI: 10.1046/j.1365-2133.2003.05595.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  38 in total

Review 1.  Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms.

Authors:  Peter M Elias; Yutaka Hatano; Mary L Williams
Journal:  J Allergy Clin Immunol       Date:  2008-03-07       Impact factor: 10.793

2.  Compliance with dysphagia recommendations by carers of adults with intellectual impairment.

Authors:  Hannah Crawford; Paula Leslie; Michael J Drinnan
Journal:  Dysphagia       Date:  2007-10       Impact factor: 3.438

3.  Barrier repair trumps immunology in the pathogenesis and therapy of atopic dermatitis.

Authors:  Peter M Elias
Journal:  Drug Discov Today Dis Mech       Date:  2008

Review 4.  "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis.

Authors:  Peter M Elias; Martin Steinhoff
Journal:  J Invest Dermatol       Date:  2008-05       Impact factor: 8.551

Review 5.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Authors:  Nicholas K Mollanazar; Peter K Smith; Gil Yosipovitch
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 6.  Lipid abnormalities and lipid-based repair strategies in atopic dermatitis.

Authors:  Peter M Elias
Journal:  Biochim Biophys Acta       Date:  2013-10-12

7.  Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches.

Authors:  Robert Sidbury; Wynnis L Tom; James N Bergman; Kevin D Cooper; Robert A Silverman; Timothy G Berger; Sarah L Chamlin; David E Cohen; Kelly M Cordoro; Dawn M Davis; Steven R Feldman; Jon M Hanifin; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Eric L Simpson; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Lawrence F Eichenfield
Journal:  J Am Acad Dermatol       Date:  2014-09-26       Impact factor: 11.527

Review 8.  Atopic dermatitis in children: clinical features, pathophysiology, and treatment.

Authors:  Jonathan J Lyons; Joshua D Milner; Kelly D Stone
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

9.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Timothy G Berger; Alfons Krol; Amy S Paller; Kathryn Schwarzenberger; James N Bergman; Sarah L Chamlin; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Steven R Feldman; Jon M Hanifin; David J Margolis; Robert A Silverman; Eric L Simpson; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2014-05-09       Impact factor: 11.527

10.  Text messages as a reminder aid and educational tool in adults and adolescents with atopic dermatitis: a pilot study.

Authors:  Venessa Pena-Robichaux; Joseph C Kvedar; Alice J Watson
Journal:  Dermatol Res Pract       Date:  2010-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.